Latest Healthcare News

Page 8 of 182
BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.
Ada Torres
Ada Torres
19 Feb 2026
TALi Digital Limited reported a 116% increase in half-year losses to $570,848 amid the integration of its recent acquisition, You Can Do It! Education. Revenue nearly doubled, reflecting early benefits from the expanded digital health and education platform.
Ada Torres
Ada Torres
19 Feb 2026
Little Green Pharma has entered a $7.8 million sale and leaseback agreement for its Western Australia production site, aiming to fuel growth in Australia and Europe while maintaining operational control.
Ada Torres
Ada Torres
19 Feb 2026
Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.
Ada Torres
Ada Torres
19 Feb 2026
Sonic Healthcare has reported a robust half-year performance, with revenue climbing 16.6% to A$5.45 billion and net profit rising 10.9%, underpinned by organic growth and key acquisitions. The company maintains its full-year guidance amid ongoing US business rationalisation.
Ada Torres
Ada Torres
19 Feb 2026
Cogstate Limited reported a solid 12% increase in revenue to $26.9 million for the half-year ended December 2025, driven by growth in its Clinical Trials segment and a 2% rise in net profit before tax. The company’s contracted future Clinical Trials revenue also grew 10%, signalling strong momentum ahead.
Ada Torres
Ada Torres
19 Feb 2026
Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.
Ada Torres
Ada Torres
19 Feb 2026
Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.
Ada Torres
Ada Torres
18 Feb 2026
Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.
Ada Torres
Ada Torres
18 Feb 2026
Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.
Ada Torres
Ada Torres
18 Feb 2026
Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.
Ada Torres
Ada Torres
18 Feb 2026
Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.
Ada Torres
Ada Torres
18 Feb 2026